In this episode of Px Pulse, we hear from AVACer Anabel Gomez about the human-centered design project she’s leading with partners in South Africa to chart a path that will better support a journey to HIV prevention. We also hear from two members of the research team—Lesego Taule and Mpumi Mbethe—who helped lead these discussions in communities where HIV is epidemic. And a program implementer for HIV prevention in South Africa, Anthony Ambrose of NACOSA, tells us how this research can be applied to programs and how it changed the way he thinks about HIV risk.
Human-Centered Design and Prevention in the Real World
The ECHO Trial Results: Time to Act
In this episode of Px Pulse. we take a look the results of the ECHO study and what they mean from several angles. Leaders of the trial, formally called Evidence for Contraceptive options in HIV Outcomes, announced study findings in mid-June. ECHO found no substantial difference in HIV acquisition among women using one of three highly effective contraceptive methods in the study: DMPA-IM, the copper IUD, the LNG implant).
The ECHO Trial: Preparing for action
In this episode of Px Pulse, AVAC spoke with two leaders from the ECHO trial team, Dr. Jared Baeten and Dr. Helen Rees, to understand what the trial can and cannot tell us. And you’ll hear leading women’s advocates from several countries where the ECHO trial took place share their demands. Carry what you learn forward as the ECHO trial raises the volume on an urgent conversation—how to empower African women around their sexual and reproductive health.
The Science of Choice: The future of HIV prevention research
This episode of Px Pulse features unmissable conversations about some of the challenges associated with today’s HIV prevention options, and analysis about what should be in the research pipeline from 2021 to 2027.
Community Engagement and HIV Prevention
In this episode of Px Pulse, we consider how future HIV prevention trials will need to be designed as HIV prevention evolves… and how to strengthen community engagement along with it. At the heart of the matter is that clinical trials for HIV prevention are set to get bigger and more complex, in response to advances in HIV prevention, such as PrEP.
AVAC Report 2018 & HIV R4P
In this episode of Px Pulse, Ntando Yola, a veteran advocate and part of the Coalition to Accelerate and Support Prevention Research (CASPR) shares his advocacy priorities for R4P and beyond. But first, AVAC’s Emily Bass talks about the just-launched 2018 annual report from AVAC, this year titled No Prevention, No End!
Combination Prevention and AIDS 2018
In this episode, featuring Ambassador Deborah Birx, we take a look at one area of great importance that was center stage at the AIDS 2018 conference in Amsterdam: primary prevention.
Cure Research and Analytic Treatment Interruption
In this episode of Px Pulse, researchers and advocates debate the rationale, risks and ethics of interrupting treatment as part of cure research. This is known as analytic treatment interruption or ATI.
HIV Vaccine Science, Research, Updates and Advocacy
With HIV Vaccine Awareness Day (HVAD) in the spotlight earlier this month, AVAC’s May episode of PxPulse features four experts steeped in HIV vaccine research. Together they help set expectations for where the field is now and where it is going.
From the Trenches, Advocates Share Their Prevention Priorities
In this episode of Px Pulse, our monthly podcast, we bring you two different conversations, each throwing a spotlight on different aspects of HIV prevention advocacy today. You’ll hear how the AVAC Partner Forum brought key issues into focus and how these advocates are sharpening their strategies. Then we turn to a global effort to accelerate prevention.